Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults. Dynacures Dyn101 development program is based on the modulation of the expression of the Dynamin 2 protein, through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, the leading bio pharmaceutical company in RNA-targeted drug discovery.
biotech, drugs, pharma
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Dynacure? We’re happy to assist you with our Startup Sourcing service.